STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer
Frontiers in Pharmacology · 09.07.2025 · 16
DOI: 10.3389/fphar.2025.1546491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.07.2025. Verfasst von Xuchen Fan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
EGFR-TKI resistance is an important factor limiting the clinical application of targeted drugs in NSCLC, but the mechanism remains unclear. The tumor microenvironment is the internal environment for cancer cells to survive, and it plays an important role in tumor resistance.
Methods
In vitro assays: CCK-8 assay, wound healing, Transwell and Colony formation assay. Protein expression analyzed via Western blot. In vivo antitumor efficacy assessed by xenograft study. Target expression in tumors confirmed by immunohistochemical staining. Statistical analysis used t-test/ANOVA (p<0.05).
Results
This study discovered that cancer associated fibroblasts (CAFs) in the tumor microenvironment induce Osimertinib resistance in NSCLC, and further study revealed that CAF-induced Osimertinib resistance in NSCLC is realized through its protein secretion. Interestingly, STAT3 is the key factor regulating CAF activation and secretion. Knockdown of STAT3 can block the secretory function of CAF, thereby reversing Osimertinib resistance in lung cancer. Furthermore, we blocked STAT3 activation in CAF with the novel STAT3 small molecule inhibitor LL1. LL1 effectively reversed CAF induced osimertinib resistance in NSCLC.
Discussion
This project contributes to a deeper understanding of the molecular mechanism of tumor microenvironment mediated EGFR-TKI resistance in NSCLC, and provides theoretical basis and experimental data for the development of novel resistance reversal agents against the tumor microenvironment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
- School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China.
- Anhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Zitieren
APA
Fan, X., Wu, S., Wu, H., Huang, Y., Tong, X., Yu, M., & Liu, Z. (2025). STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1546491
Vancouver
Fan X, Wu S, Wu H, Huang Y, Tong X, Yu M, et al. STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1546491
BibTeX
@article{Fan2025,
author = {Fan, Xuchen and Wu, Sheng and Wu, Honglong and Huang, Yingying and Tong, Xuhui and Yu, Meiling and Liu, Zhe},
title = {STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1546491}
}
EUVIMED